US 12,110,325 B2
TM4SF5-targeting humanized antibody and use thereof
Se Mi Kim, Daejeon (KR); Jung Weon Lee, Hanam-si (KR); Dongjoon Ko, Daejeon (KR); Junghwa Yoon, Daejeon (KR); Eunmi Kim, Seoul (KR); Seo Hee Nam, Daejeon (KR); and Eun Ae Shin, Suwon-si (KR)
Assigned to KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, Daejeon (KR); and SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, Seoul (KR)
Filed by KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, Daejeon (KR); and SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, Seoul (KR)
Filed on Jan. 13, 2023, as Appl. No. 18/154,597.
Claims priority of application No. 10-2022-0005907 (KR), filed on Jan. 14, 2022.
Prior Publication US 2023/0279104 A1, Sep. 7, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 43/00 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 43/00 (2018.01); C12N 15/63 (2013.01); C07K 2317/565 (2013.01)] 12 Claims
 
1. An antibody or antigen-binding fragment thereof, that binds to transmembrane 4 L6 family member 5 (TM4SF5), comprising:
a heavy chain variable domain comprising the sequence of SEQ ID NO: 7, which comprises HCDR1 comprising the sequence of SEQ ID NO: 9; HCDR2 comprising the sequence of SEQ ID NO: 10; and HCDR3 comprising the sequence of SEQ ID NO: 3; and
a light chain variable domain comprising the sequence of SEQ ID NO: 8, which comprises LCDR1 comprising the sequence of SEQ ID NO: 4; LCDR2 comprising the sequence of SEQ ID NO: 5; and LCDR3 comprising the sequence of SEQ ID NO: 6,
wherein the CDR sequences of SEQ ID NOS: 9 and 10 are assigned according to the numbering system of Chothia.